CGM
Using devices and systems that have not been authorized by the regulatory agency comes with a risk.
Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99.
Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform.
Dexcom announced a slew of announcements this morning including an integration with Google Fit, a feature that lets users share their readings with 10 people and a technical inquiries feature.
Ascensia will launch a version of POCTech's device this year, then collaborate on co-developing the next generation.
The clearance brings US readers a feature long available in Europe, and paves the way for data plays.
The market comprised $98 million in revenue during 2017, and is beginning to move away from stand-alone devices or apps.
Realtime blood glucose information will allow Livongo's platform to deliver more insights, coaching to people with diabetes.